AR044337A1 - Procedimiento para potenciar la cognicion usando ziprasidona - Google Patents
Procedimiento para potenciar la cognicion usando ziprasidonaInfo
- Publication number
- AR044337A1 AR044337A1 ARP040101652A ARP040101652A AR044337A1 AR 044337 A1 AR044337 A1 AR 044337A1 AR P040101652 A ARP040101652 A AR P040101652A AR P040101652 A ARP040101652 A AR P040101652A AR 044337 A1 AR044337 A1 AR 044337A1
- Authority
- AR
- Argentina
- Prior art keywords
- mammal
- formula
- ziprasidone
- human
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 4
- 230000019771 cognition Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229960000607 ziprasidone Drugs 0.000 abstract 3
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000036626 Mental retardation Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009329 sexual behaviour Effects 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010022524 Intentional self-injury Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005560 Self Mutilation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Procedimiento de uso de los compuestos piperazinil-heterocíclicos de fórmula (1), para potenciar la cognición en un mamífero, incluyendo un ser humano, por ejemplo un mamífero aquejado de psicosis, autismo, demencia, o retraso mental, que comprende la administración de una cantidad eficaz de un compuesto de fórmula (1) (por ejemplo, ziprasidona) al mamífero. Procedimiento para reducir o mejorar en un mamífero, incluyendo un ser humano, aquejado de un trastorno o afección seleccionado entre autismo, retraso mental, trastorno obsesivo compulsivo, y demencia, los síntomas positivos (por ejemplo, agresión excesiva, conducta sexual desinhibida, conducta sexual inapropiada, agitación, conducta compulsiva tal como golpearse la cabeza, retorcerse los labios, automutilación, o conducta estereotípica) asociados a los trastornos o afecciones anteriormente mencionados, dicho procedimiento comprende la administración de una cantidad eficaz de un compuesto de fórmula (1) (por ejemplo, ziprasidona) al mamífero. Procedimiento para tratar el trastorno bipolar pediátrico en un mamífero, incluyendo un ser humano, dicho procedimiento comprende la administración de una cantidad eficaz de un compuesto de fórmula (1), (por ejemplo, ziprasidona) al mamífero. Los compuestos de la fórmula (1), se definen como sigue, o una sal de adición de ácidos farmacéuticamente aceptable del mismo, en la que Ar, n, X, e Y son como se han definido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47137903P | 2003-05-16 | 2003-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044337A1 true AR044337A1 (es) | 2005-09-07 |
Family
ID=33452442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101652A AR044337A1 (es) | 2003-05-16 | 2004-05-14 | Procedimiento para potenciar la cognicion usando ziprasidona |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050014764A1 (es) |
| EP (1) | EP1626722A1 (es) |
| JP (1) | JP2006528236A (es) |
| AR (1) | AR044337A1 (es) |
| BR (1) | BRPI0419067A (es) |
| CA (2) | CA2525323A1 (es) |
| MX (1) | MXPA05012325A (es) |
| TW (1) | TW200507847A (es) |
| WO (1) | WO2004100956A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| EP2292220A3 (en) | 2005-11-22 | 2012-01-04 | Orexigen Therapeutics, Inc. | Composition and methods for increasing insulin sensitivity |
| BRPI0707223A2 (pt) * | 2006-01-27 | 2011-04-26 | Pfizer Prod Inc | compostos de derivados de aminoftalazina |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| BRPI0719210A2 (pt) * | 2006-10-12 | 2015-05-05 | Xenon Pharmaceuticals Inc | Uso de compostos espiro-oxindol como agentes terapêuticos |
| JP2010522690A (ja) * | 2006-10-12 | 2010-07-08 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 三環式スピロオキシインドール誘導体および治療薬としてのその使用 |
| EP2076514A1 (en) * | 2006-10-12 | 2009-07-08 | Xenon Pharmaceuticals Inc. | Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| BRPI0813001A2 (pt) * | 2007-06-29 | 2019-09-24 | Univ Emory | composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica |
| EP2296658A4 (en) * | 2008-05-09 | 2014-01-15 | Univ Emory | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
| CN102946859B (zh) | 2010-02-26 | 2016-03-02 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| EP2569301A1 (en) | 2010-05-12 | 2013-03-20 | Abbvie Inc. | Indazole inhibitors of kinase |
| KR20220042241A (ko) | 2012-06-06 | 2022-04-04 | 오렉시젠 세러퓨틱스 인크. | 과체중 및 비만의 치료 방법 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| CZ289216B6 (cs) * | 1996-05-07 | 2001-12-12 | Pfizer Inc. | Trihydrát methansulfonátu 5-(2-(4-(1,2-benzizothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-onu, farmaceutická kompozice a léčivo na jeho bázi |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| EP1165027A1 (en) * | 1999-03-30 | 2002-01-02 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
| AU4062900A (en) * | 1999-04-06 | 2000-10-23 | Sepracor, Inc. | Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
-
2004
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en not_active Ceased
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2525323A1 (en) | 2004-11-25 |
| JP2006528236A (ja) | 2006-12-14 |
| MXPA05012325A (es) | 2006-01-30 |
| CA2625837A1 (en) | 2004-11-25 |
| US20080269246A1 (en) | 2008-10-30 |
| BRPI0419067A (pt) | 2007-12-11 |
| EP1626722A1 (en) | 2006-02-22 |
| US20050014764A1 (en) | 2005-01-20 |
| TW200507847A (en) | 2005-03-01 |
| WO2004100956A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044337A1 (es) | Procedimiento para potenciar la cognicion usando ziprasidona | |
| ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| CA2801241C (en) | Methods for treating bipolar disorder | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| EA200501098A1 (ru) | Антибактериальные агенты | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| AR046272A1 (es) | Inhibidores de dipeptidil peptidasa iv | |
| BRPI0919020A2 (pt) | Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris | |
| CR7510A (es) | DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
| CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
| AR015448A1 (es) | COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN | |
| EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| MX2010004314A (es) | Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso. | |
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |